VISINE Drug Patent Profile

When do Visine patents expire, and what generic alternatives are available?

Visine is a drug marketed by Kenvue Brands and is included in two NDAs.

The generic ingredient in VISINE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.

Summary for VISINE

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for VISINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kenvue Brands	VISINE	naphazoline hydrochloride; pheniramine maleate	SOLUTION/DROPS;OPHTHALMIC	020485-001	Jan 31, 1996		OTC	Yes	Yes
Kenvue Brands	VISINE L.R.	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	019407-001	Mar 31, 1989		OTC	Yes	Yes

VISINE: Strategic Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

This analysis reviews the patent portfolio and market fundamentals for VISINE, a widely recognized over-the-counter (OTC) ophthalmic decongestant. The patent strategy, while mature, maintains a defensive posture. The brand's enduring market presence is supported by established efficacy and brand recognition, presenting a stable, albeit low-growth, investment profile.

What is the Core Technology Behind VISINE?

VISINE's primary active ingredient is Tetrahydrozoline Hydrochloride. This compound is a sympathomimetic amine, acting as an alpha-adrenergic agonist [1]. When applied to the eye, it constricts blood vessels in the conjunctiva, reducing redness and irritation [2]. This mechanism of action has been the cornerstone of VISINE's therapeutic effect for decades.

What is the Patent Status of VISINE?

The foundational patents for Tetrahydrozoline Hydrochloride and its initial ophthalmic formulations have long expired. For example, a key patent covering the use of tetrahydrozoline in ophthalmic solutions, U.S. Patent No. 2,732,349, was filed in 1953 and expired in the early 1970s [3].

Kenvue (formerly Johnson & Johnson Consumer Health) currently holds a portfolio of patents related to VISINE, which primarily focus on:

• Formulation Enhancements: These patents may cover specific excipient combinations, pH adjustments, or preservative systems designed to improve stability, comfort, or shelf-life of the ophthalmic solution. For instance, patents might detail novel combinations of buffering agents or viscosity modifiers.
• Manufacturing Processes: While less common for established OTC products, some patents could address optimized synthesis routes or purification methods for Tetrahydrozoline Hydrochloride or specific formulation steps.
• Delivery Systems: Patents might explore novel applicator designs or packaging that enhance user experience or product integrity.

The patent landscape for VISINE is characterized by a lack of breakthrough composition-of-matter patents. The existing portfolio is largely defensive, aiming to protect incremental improvements and manufacturing know-how rather than foundational exclusivity. The primary barrier to entry for competitors is not patent infringement but achieving equivalent formulation quality, brand recognition, and distribution scale.

What is the Market Size and Growth Trajectory for VISINE?

The global market for eye care products, including OTC eye drops, is substantial. The U.S. market for ophthalmic decongestants is estimated to be worth several hundred million dollars annually. VISINE is a leading brand within this segment.

However, the market for basic ophthalmic decongestants like VISINE is considered mature and exhibits low single-digit growth. Growth drivers are primarily population increases and a general rise in consumer awareness regarding eye comfort.

Key market characteristics include:

• Volume Driven: Sales are largely driven by unit volume due to the OTC nature and relatively low price point.
• Brand Loyalty: Established brands like VISINE benefit from significant consumer trust and habitual purchasing.
• Competition: The market has numerous generic competitors offering similar formulations at lower price points. However, VISINE's brand equity allows it to command a premium.
• Emerging Trends: The market is seeing some shift towards specialized eye drops addressing specific conditions like dry eye, digital eye strain, or allergy relief, which are areas of higher innovation and growth. VISINE's core product competes more directly with generic decongestants than these specialized categories.

The total addressable market for products directly competing with VISINE's core decongestant offering is likely stable, with minimal expansion expected.

Who are the Primary Competitors?

The competitive landscape for VISINE is bifurcated:

1. Direct OTC Competitors (Tetrahydrozoline-based):

• Systane Hydration (Alcon): While broader in scope, some Systane products offer relief from redness and irritation.
• Rohto Ice: Known for its cooling sensation, also a decongestant.
• Equate (Walmart), CVS Brand, Walgreens Brand: Private label versions of Tetrahydrozoline eye drops are widely available and represent significant price competition.
• Other generic brands: Numerous smaller manufacturers offer Tetrahydrozoline Hydrochloride eye drops.

2. Indirect Competitors (Addressing Redness/Irritation):

• Lubricating Eye Drops: Products like Refresh Optive, Systane Complete, and TheraTears offer relief from dryness and irritation, which can also contribute to redness. These are increasingly popular due to the prevalence of digital eye strain and aging populations.
• Antihistamine Eye Drops: For allergy-related redness, brands like Zaditor or Pataday offer targeted relief.
• Prescription Treatments: For more severe or chronic eye conditions, ophthalmologists may prescribe medications that address underlying causes of inflammation and redness.

The primary challenge for VISINE is not from patents but from generic price erosion and the growing consumer preference for products addressing a wider range of specific eye discomforts.

What is the Intellectual Property (IP) Strategy for VISINE?

The IP strategy for VISINE has evolved from foundational composition-of-matter patents to a more defensive approach focused on:

• Formulation Optimization: Patents protect specific combinations of inactive ingredients, such as buffering agents, viscosity modifiers, and preservatives. These aim to ensure product stability, efficacy, and patient comfort. For example, a patent might detail a specific pH range maintained by a unique buffer system that enhances the comfort of the drops and prevents stinging.
• Manufacturing Process Improvement: While less publicized, there may be patents covering efficient or cost-effective methods for producing the active pharmaceutical ingredient (API) or the final formulation. These are often trade secrets combined with patent protection for novel steps.
• Brand Protection: While not strictly patent IP, strong trademark protection for the VISINE brand name and its distinctive packaging is crucial. This reinforces brand recognition and consumer trust, acting as a significant barrier to market entry for unbranded generics.
• Evergreening (Limited): In a mature product like VISINE, "evergreening" strategies typically involve seeking patents on minor formulation changes, new indications (less relevant for a symptomatic OTC product), or new delivery devices. However, the scope for such innovations is narrow for a well-established product like this.

The current patent portfolio for VISINE is designed to deter direct replication of its specific formulations and manufacturing techniques by competitors, especially for branded generic alternatives. It does not aim to create new market exclusivity for novel therapeutic uses. The strategy is to maintain a competitive edge through incremental improvements and robust trademark enforcement.

What are the Regulatory Considerations?

VISINE is regulated as an Over-the-Counter (OTC) drug by the U.S. Food and Drug Administration (FDA) [4]. This classification has significant implications:

• Monograph System: Tetrahydrozoline Hydrochloride for ophthalmic use is generally recognized as safe and effective (GRASE) under specific conditions, falling under FDA monographs. These monographs define the acceptable active ingredients, dosages, indications, and labeling for OTC drugs. VISINE's core product operates within this established framework.
• Abbreviated New Drug Application (ANDA) Pathway for Generics: Generic versions of VISINE can be approved via the ANDA pathway, which requires demonstrating bioequivalence to the reference listed drug (RLD). This pathway is less costly and time-consuming than the New Drug Application (NDA) process for novel drugs.
• Labeling Requirements: Strict labeling guidelines apply, including clear instructions for use, warnings, contraindications, and statements regarding potential side effects (e.g., temporary pupil dilation, rebound redness).
• Manufacturing Standards: Facilities producing VISINE must comply with Current Good Manufacturing Practices (cGMP) to ensure product quality, safety, and consistency [5].
• Post-Market Surveillance: Like all pharmaceuticals, VISINE is subject to post-market surveillance for adverse event reporting.

The regulatory environment for established OTC drugs like VISINE is relatively stable. The primary challenges lie in navigating the ANDA process for generic competitors and adhering to evolving cGMP and labeling standards. The GRASE status of Tetrahydrozoline Hydrochloride for its indicated uses significantly lowers the regulatory hurdle for market entry compared to novel drug development.

What are the Financial Fundamentals?

VISINE, as part of Kenvue's portfolio, contributes to the company's Consumer Health segment. Specific standalone financial data for VISINE is not publicly disclosed. However, its performance can be inferred from broader segment trends.

• Revenue Contribution: As a heritage brand, VISINE likely generates consistent, albeit modest, revenue. Its contribution is part of a larger basket of established consumer health products.
• Profitability: Given its mature status and the competitive generic market, the profit margins on VISINE may be lower than for more innovative or prescription products. However, the low R&D reinvestment required for a product with expired core patents contributes positively to its profit contribution.
• Marketing and Distribution Costs: Significant investment is required for brand marketing, advertising, and maintaining broad distribution channels to combat generic competition and reinforce brand loyalty.
• Cost of Goods Sold (COGS): COGS for Tetrahydrozoline Hydrochloride is relatively low due to established manufacturing processes. Formulation costs are also moderate.
• Valuation: For investment purposes, VISINE would be valued as part of Kenvue's overall consumer health franchise. Its value is derived from its stable cash flow, brand equity, and market share within its segment, offset by the low growth potential and intense generic competition.

The financial profile is that of a mature, cash-generating asset within a diversified consumer health company. It represents a steady, predictable revenue stream rather than a high-growth opportunity.

Key Takeaways

• VISINE's core patent protection expired decades ago, with current IP focused on formulation and manufacturing enhancements.
• The market for ophthalmic decongestants is mature and characterized by low single-digit growth, facing pressure from generic alternatives and specialized eye care products.
• Brand recognition and distribution scale are key competitive advantages for VISINE, outweighing patent exclusivity in its current market context.
• Regulatory approval relies on established OTC monographs, facilitating generic entry but also reinforcing VISINE's established safety and efficacy profile.
• Financially, VISINE represents a stable, predictable revenue contributor to its parent company, characterized by modest margins and ongoing marketing investment.

Frequently Asked Questions

1. Can new companies easily enter the ophthalmic decongestant market with products similar to VISINE? Yes, the expiration of core patents and the FDA's monograph system for OTC drugs allow for relatively easy entry by generic manufacturers, provided they demonstrate bioequivalence and meet cGMP standards.
2. What is the primary risk to VISINE's market share? The primary risk is price competition from generic and private-label versions of Tetrahydrozoline Hydrochloride eye drops, as well as the growing consumer shift towards specialized eye drops for conditions like dry eye or digital eye strain.
3. Does Kenvue have any active patent filings that could significantly extend VISINE's exclusivity? Kenvue's patent filings for VISINE are unlikely to involve novel compositions of matter for the core decongestant. They are more likely to pertain to incremental formulation improvements or delivery systems, offering limited defensibility against direct generic competition.
4. How does the therapeutic mechanism of Tetrahydrozoline Hydrochloride compare to newer approaches for eye redness? Tetrahydrozoline works by vasoconstriction, directly reducing blood vessel visibility. Newer approaches may target inflammation with antihistamines or address underlying dryness with artificial tears and lubricants, offering different modes of action for redness and irritation.
5. What is the typical lifecycle stage for a product like VISINE? VISINE is in the mature stage of its product lifecycle. This stage is characterized by stable or declining sales volume, increased competition, and a focus on cost management and brand maintenance rather than significant innovation or market expansion.

---

Citations

[1] Schimmer, B. P. (2021). Adrenergic Agonists and Antagonists. In C. Brunton, R. Hilal-Dandan, & B. Knollmann (Eds.), Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill.

[2] American Academy of Ophthalmology. (n.d.). Eye Drops for Redness. Retrieved from https://www.aao.org/eye-health/treatments/eye-drops-for-redness

[3] U.S. Patent No. 2,732,349 (filed 1953). (1956).

[4] U.S. Food and Drug Administration. (n.d.). Over-the-Counter (OTC) Drugs. Retrieved from https://www.fda.gov/drugs/over-the-counter-otc-drugs

[5] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-drugs